{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:32:08Z","timestamp":1783398728158,"version":"3.54.6"},"reference-count":144,"publisher":"Bentham Science Publishers Ltd.","issue":"46","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a major health concern\nworldwide and has evolved into different variants. SARS-CoV-2 possesses a spike glycoprotein on its envelope\nthat binds to the angiotensin-converting enzyme 2 (ACE-2) receptor of the host cell via the receptor-binding\ndomain (RBD) in the upper respiratory tract. Since the SARS-CoV-2 virus variants change the severity of the\ndiesease and treatment scenarios, repurposing current medicines may provide a quick and appealing method\nwith established safety features. The efficacy and safety of antiviral medicines against the coronavirus disease\n2019 (COVID-19) have been investigated, and several of them are now undergoing clinical studies. Recently, it\nhas been found that nitric oxide (NO) shows antiviral properties against SARS-CoV-2 and prevents the virus\nfrom binding to a host cell. In addition, NO is a well-known vasodilator and acts as an important coagulation\nmediator. With the fast-track development of COVID-19 treatments and vaccines, one avenue of research\naimed at improving therapeutics is exploring different forms of drug delivery, including intranasal sprays and\ninhalation therapy. The nasal mucosa is more prone to be the site of infection as it is in more direct contact with\nthe physical environment via air during inhalation and exhalation. Thus, the use of exogenous nasal NO therapy\nvia the intranasal route displays a distinct advantage. Therefore, the objective of this review is to summarize the\nrelevant actions of NO via the intranasal spray and inhalation delivery, its mechanism of action, and its use in\nthe treatment of COVID-19.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612829666221024124848","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T04:30:15Z","timestamp":1666758615000},"page":"3658-3670","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Nitric Oxide and its Derivatives Containing Nasal Spray and Inhalation Therapy for\nthe Treatment of COVID-19"],"prefix":"10.2174","volume":"28","author":[{"given":"Vivek P.","family":"Chavda","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics and Pharmaceutical Technology, LM College of Pharmacy, Ahmedabad - 380009, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalitkumar K.","family":"Vora","sequence":"first","affiliation":[{"name":"School of\nPharmacy, Queen\u2019s University Belfast, 97 Lisburn Road, BT9 7BL, U.K"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3353-7897","authenticated-orcid":true,"given":"Rajeev K.","family":"Singla","sequence":"first","affiliation":[{"name":"Institutes for Systems Genetics, Frontiers Science Center\nfor Disease-Related Molecular Network, West China Hospital, Sichuan University, Xinchuan Road 2222, Chengdu, Sichuan, China"},{"name":"School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab-144411, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aayushi B.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Pharmaceutical Technology, LM College of Pharmacy, Ahmedabad - 380009, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyal","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Pharmaceutical Technology, LM College of Pharmacy, Ahmedabad - 380009, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir N.","family":"Uversky","sequence":"additional","affiliation":[{"name":"Department of Molecular\nMedicine and Byrd Alzheimer\u2019s Research Institute, Morsani College of Medicine, University of South Florida, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasso","family":"Apostolopoulos","sequence":"additional","affiliation":[{"name":"Institute for Health and Sport, Victoria University, Melbourne VIC 3030, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"100086","DOI":"10.1016\/j.crphar.2022.100086","volume":"3","author":"Basu D.","year":"2022","unstructured":"Basu D.; Chavda V.P.; Mehta A.A.; Therapeutics for COVID-19 and post COVID-19 complications: An update. Curr Res Pharmacol Drug Discov 2022,3,100086","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"ref=2","first-page":"130","year":"2020","unstructured":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines Natl Inst Heal COVID-19 Treatment Guidelines PanelAvailable from: 2020,130","journal-title":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines Natl Inst Heal"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3390\/vaccines9060631","volume":"9","author":"Chavda V.P.","year":"2021","unstructured":"Chavda V.P.; Feehan J.; Apostolopoulos V.; A veterinary vaccine for sars-cov-2: the first COVID-19 vaccine for animals. Vaccines (Basel) 2021,9(6),631","journal-title":"Vaccines (Basel)"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12929-020-00695-2","volume":"27","author":"Li Y.D.","year":"2020","unstructured":"Li Y.D.; Chi W.Y.; Su J.H.; Ferrall L.; Hung C.F.; Wu T.C.; Coronavirus vaccine development: from SARS and MERS to COVID-19. J Biomed Sci 2020,27(1),104","journal-title":"J Biomed Sci"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1021\/acscentsci.0c00501","volume":"6","author":"Carter L.J.","year":"2020","unstructured":"Carter L.J.; Garner L.V.; Smoot J.W.; Assay techniques and test development for COVID-19 diagnosis. ACS Cent Sci 2020,6(5),591-605","journal-title":"ACS Cent Sci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s00112-021-01158-0","volume":"169","author":"Kerbl R.","year":"2021","unstructured":"Kerbl R.; Zepp F.; Coronavirus disease 2019. Monatsschr Kinderheilkd 2021,169(4),308-311","journal-title":"Monatsschr Kinderheilkd"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/vaccines10030367","volume":"10","author":"Chavda V.P.","year":"2022","unstructured":"Chavda V.P.; Apostolopoulos V.; Is booster dose strategy sufficient for omicron variant of sars-cov-2? Vaccines (Basel) 2022,10(3),367","journal-title":"Vaccines (Basel)"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.maturitas.2022.01.011","volume":"158","author":"Chavda V.P.","year":"2022","unstructured":"Chavda V.P.; Apostolopoulos V.; Omicron variant (B.1.1.529) of SARS-CoV-2: Threat for the elderly? Maturitas 2022,158,78-81","journal-title":"Maturitas"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1080\/14760584.2022.2044800","volume":"21","author":"Chavda V.P.","year":"2022","unstructured":"Chavda V.P.; Apostolopoulos V.; Global impact of delta plus variant and vaccination. Expert Rev Vaccines 2022,21(5),597-600","journal-title":"Expert Rev Vaccines"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2217\/imt-2022-0064","volume":"14","author":"Chavda V.P.","year":"2022","unstructured":"Chavda V.P.; Hanuma Kumar Ghali E.N.; Yallapu M.M.; Apostolopoulos V.; Therapeutics to tackle Omicron outbreak. Immunotherapy 2022,14(11),833-838","journal-title":"Immunotherapy"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1002\/jmv.27717","volume":"94","author":"Chavda V.P.","year":"2022","unstructured":"Chavda V.P.; Patel A.B.; Vaghasiya D.D.; SARS\u2010CoV\u20102 variants and vulnerability at the global level. J Med Virol 2022,94(7),2986-3005","journal-title":"J Med Virol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3390\/v14040759","volume":"14","author":"Chavda V.P.","year":"2022","unstructured":"Chavda V.P.; Bezbaruah R.; Athalye M.; Replicating viral vector-based vaccines for COVID-19: Potential avenue in vaccination arena. Viruses 2022,14(4),759","journal-title":"Viruses"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","volume":"46","author":"Zhang H.","year":"2020","unstructured":"Zhang H.; Penninger J.M.; Li Y.; Zhong N.; Slutsky A.S.; Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020,46(4),586-590","journal-title":"Intensive Care Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"100004","DOI":"10.1016\/j.ccmp.2021.100004","volume":"1","author":"Chavda V.P.","year":"2021","unstructured":"Chavda V.P.; Vora L.K.; Vihol D.R.; COVAX-19&#x24C7; Vaccine: Completely blocks virus transmission to non-immune individuals. Clin Compl Med Pharmacol 2021,1(1),100004","journal-title":"Clin Compl Med Pharmacol"},{"key":"ref=15","first-page":"7","year":"2022","unstructured":"WHO Coronavirus (COVID-19) Dashboard WHOAvailable from:  (accessed September 5, 2022).2022,7","journal-title":"WHO Coronavirus (COVID-19) Dashboard"},{"key":"ref=16","first-page":"1","year":"2021","unstructured":"COVID-19 weekly epidemiological update 35. World Heal Organ 2021,1-3","journal-title":"World Heal Organ"},{"key":"ref=17","first-page":"1","year":"2021","unstructured":"COVID-19 weekly epidemiological update 22. World Heal Organ World Health Organization2021,1-3","journal-title":"World Heal Organ"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"100093","DOI":"10.1016\/j.cscee.2021.100093","volume":"3","author":"Mazumder P.","year":"2021","unstructured":"Mazumder P.; Kalamdhad A.; Chaminda G.G.T.; Kumar M.; Coalescence of co-infection and antimicrobial resistance with SARS-CoV-2 infection: The blues of post-COVID-19 world. Case Stud Chem Environ Eng 2021,3,100093","journal-title":"Case Stud Chem Environ Eng"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","volume":"326","author":"Al Kaabi N.","year":"2021","unstructured":"Al Kaabi N.; Zhang Y.; Xia S.; Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults. JAMA 2021,326(1),35-45","journal-title":"JAMA"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1177\/15353702221092984","volume":"247","author":"Krishnan A.","year":"2022","unstructured":"Krishnan A.; Gangadaran P.; Chavda V.P.; Convalescent serum-derived exosomes: Attractive niche as COVID-19 diagnostic tool and vehicle for mRNA delivery. Exp Biol Med (Maywood) 2022,247(14),1244-1252","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/ane.13266","volume":"142","author":"Whittaker A.","year":"2020","unstructured":"Whittaker A.; Anson M.; Harky A.; Neurological Manifestations of COVID\u201019: A systematic review and current update. Acta Neurol Scand 2020,142(1),14-22","journal-title":"Acta Neurol Scand"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1164\/rccm.201503-0584OC","volume":"193","author":"Riviello E.D.","year":"2016","unstructured":"Riviello E.D.; Kiviri W.; Twagirumugabe T.; Hospital incidence and outcomes of the acute respiratory distress syndrome using the Kigali modification of the Berlin definition. Am J Respir Crit Care Med 2016,193(1),52-59","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1007\/s10072-020-04801-y","volume":"41","author":"Favas T.T.","year":"2020","unstructured":"Favas T.T.; Dev P.; Chaurasia R.N.; Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions. Neurol Sci 2020,41(12),3437-3470","journal-title":"Neurol Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1001\/jama.2020.6771","volume":"323","author":"Spinato G.","year":"2020","unstructured":"Spinato G.; Fabbris C.; Polesel J.; Alterations in smell or taste in mildly symptomatic outpatients with sars-cov-2 infection. JAMA 2020,323(20),2089-2090","journal-title":"JAMA"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"100083","DOI":"10.1016\/j.jtauto.2021.100083","volume":"4","author":"Agresti N.","year":"2021","unstructured":"Agresti N.; Lalezari J.P.; Amodeo P.P.; Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab. J Transl Autoimmun 2021,4,100083","journal-title":"J Transl Autoimmun"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2002197","DOI":"10.1183\/13993003.02197-2020","volume":"56","author":"Spruit M.A.","year":"2020","unstructured":"Spruit M.A.; Holland A.E.; Singh S.J.; Tonia T.; Wilson K.C.; Troosters T.; COVID-19: interim guidance on rehabilitation in the hospital and post-hospital phase from a European Respiratory Society- and American Thoracic Society-coordinated international task force. Eur Respir J 2020,56(6),2002197","journal-title":"Eur Respir J"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","volume":"12","author":"Keller L.A.","year":"2022","unstructured":"Keller L.A.; Merkel O.; Popp A.; Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res 2022,12(4),735-757","journal-title":"Drug Deliv Transl Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/CCM.0000000000002255","volume":"45","author":"Rhodes A.","year":"2017","unstructured":"Rhodes A.; Evans L.E.; Alhazzani W.; Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Crit Care Med 2017,45(3),486-552","journal-title":"Crit Care Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"100013","DOI":"10.1016\/j.ejmcr.2021.100013","volume":"3","author":"Chavda V.P.","year":"2021","unstructured":"Chavda V.P.; Gajjar N.; Shah N.; Dave D.J.; Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment. Europ J Med Chem Rep 2021,3,100013","journal-title":"Europ J Med Chem Rep"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.resp.2012.04.004","volume":"184","author":"Olson K.R.","year":"2012","unstructured":"Olson K.R.; Donald J.A.; Dombkowski R.A.; Perry S.F.; Evolutionary and comparative aspects of nitric oxide, carbon monoxide and hydrogen sulfide. Respir Physiol Neurobiol 2012,184(2),117-129","journal-title":"Respir Physiol Neurobiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"m3379","DOI":"10.1136\/bmj.m3379","volume":"370","author":"Agarwal A.","year":"2020","unstructured":"Agarwal A.; Rochwerg B.; Lamontagne F.; A living WHO guideline on drugs for covid-19. BMJ 2020,370,m3379","journal-title":"BMJ"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.maturitas.2021.07.009","volume":"154","author":"Chavda V.P.","year":"2021","unstructured":"Chavda V.P.; Apostolopoulos V.; Mucormycosis-An opportunistic infection in the aged immunocompromised individual: A reason for concern in COVID-19. Maturitas 2021,154,58-61","journal-title":"Maturitas"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"62887","DOI":"10.1007\/s11356-022-21967-4","volume":"29","author":"Chavda V.P.","year":"2022","unstructured":"Chavda V.P.; Sonak S.S.; Munshi N.K.; Dhamade P.N.; Pseudoscience and fraudulent products for COVID-19 management. Environ Sci Pollut Res Int 2022,29(42),62887-62912","journal-title":"Environ Sci Pollut Res Int"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"114184","DOI":"10.1016\/j.bcp.2020.114184","volume":"180","author":"Chakraborty R.","year":"2020","unstructured":"Chakraborty R.; Parvez S.; COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials. Biochem Pharmacol 2020,180,114184","journal-title":"Biochem Pharmacol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1016\/j.drudis.2021.07.021","volume":"26","author":"Chavda V.P.","year":"2021","unstructured":"Chavda V.P.; Vora L.K.; Pandya A.K.; Patravale V.B.; Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management. Drug Discov Today 2021,26(11),2619-2636","journal-title":"Drug Discov Today"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jinf.2021.05.009","volume":"83","author":"Winchester S.","year":"2021","unstructured":"Winchester S.; John S.; Jabbar K.; John I.; Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection. J Infect 2021,83(2),237-279","journal-title":"J Infect"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1080\/14760584.2021.1987223","volume":"20","author":"Chavda V.P.","year":"2021","unstructured":"Chavda V.P.; Pandya R.; Apostolopoulos V.; DNA vaccines for SARS-CoV-2: toward third-generation vaccination era. Expert Rev Vaccines 2021,20(12),1549-1560","journal-title":"Expert Rev Vaccines"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3390\/biologics1030020","volume":"1","author":"Chavda V.P.","year":"2021","unstructured":"Chavda V.P.; Hossain M.K.; Beladiya J.; Apostolopoulos V.; Nucleic acid vaccines for COVID-19: a paradigm shift in the vaccine development arena. Biologics 2021,1(3),337-356","journal-title":"Biologics"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"587269","DOI":"10.3389\/fcimb.2020.587269","volume":"10","author":"Wang M.Y.","year":"2020","unstructured":"Wang M.Y.; Zhao R.; Gao L.J.; Gao X.F.; Wang D.P.; Cao J.M.; SARS-CoV-2: Structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol 2020,10,587269","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1007\/s00330-020-06748-2","volume":"30","author":"Kim H.","year":"2020","unstructured":"Kim H.; Outbreak of novel coronavirus (COVID-19): What is the role of radiologists? Eur Radiol 2020,30(6),3266-3267","journal-title":"Eur Radiol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1208\/s12248-020-00532-2","volume":"23","author":"Majumder J.","year":"2021","unstructured":"Majumder J.; Minko T.; Recent developments on therapeutic and diagnostic approaches for COVID-19. AAPS J 2021,23(1),14","journal-title":"AAPS J"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/postgradmedj-2020-138577","volume":"97","author":"Parasher A.","year":"2021","unstructured":"Parasher A.; COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. BMJ 2021,97(1147),312-320","journal-title":"BMJ"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"173890","DOI":"10.1016\/j.ejphar.2021.173890","volume":"895","author":"Tarighi P.","year":"2021","unstructured":"Tarighi P.; Eftekhari S.; Chizari M.; Sabernavaei M.; Jafari D.; Mirzabeigi P.; A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. Eur J Pharmacol 2021,895,173890","journal-title":"Eur J Pharmacol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/14787210.2020.1813024","volume":"19","author":"Echeverr&#xED;a-Esnal D.","year":"2021","unstructured":"Echeverr&#xED;a-Esnal D.; Martin-Ontiyuelo C.; Navarrete-Rouco M.E.; Azithromycin in the treatment of COVID-19: A review. Expert Rev Anti Infect Ther 2021,19(2),147-163","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/cpt.1857","volume":"108","author":"Damle B.","year":"2020","unstructured":"Damle B.; Vourvahis M.; Wang E.; Leaney J.; Corrigan B.; Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID\u201019. Clin Pharmacol Ther 2020,108(2),201-211","journal-title":"Clin Pharmacol Ther"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2020.08.011","volume":"551","author":"Seyed Hosseini E.","year":"2020","unstructured":"Seyed Hosseini E.; Riahi Kashani N.; Nikzad H.; Azadbakht J.; Hassani Bafrani H.; Haddad Kashani H.; The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. Virology 2020,551,1-9","journal-title":"Virology"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"Horby P.","year":"2021","unstructured":"Horby P.; Lim W.S.; Emberson J.R.; Dexamethasone in hospitalized patients with covid-19. N Engl J Med 2021,384(8),693-704","journal-title":"N Engl J Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/myc.13256","volume":"64","author":"Ahmadikia K.","year":"2021","unstructured":"Ahmadikia K.; Hashemi S.J.; Khodavaisy S.; The double\u2010edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza\u2010associated mucormycosis versus COVID\u201019 associated mucormycosis. Mycoses 2021,64(8),798-808","journal-title":"Mycoses"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3949\/ccjm.87c.12005","volume":"87","author":"Kow C.S.","year":"2020","unstructured":"Kow C.S.; Hasan S.S.; Dexamethasone or hydrocortisone in COVID-19? Cleve Clin J Med 2020,87(12),715","journal-title":"Cleve Clin J Med"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ijid.2020.10.069","volume":"102","author":"Joshi S.","year":"2021","unstructured":"Joshi S.; Parkar J.; Ansari A.; Role of favipiravir in the treatment of COVID-19. Int J Infect Dis 2021,102,501-508","journal-title":"Int J Infect Dis"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.mjafi.2020.08.004","volume":"76","author":"Agrawal U.","year":"2020","unstructured":"Agrawal U.; Raju R.; Udwadia Z.F.; Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India 2020,76(4),370-376","journal-title":"Med J Armed Forces India"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s43440-020-00155-6","volume":"72","author":"Singh T.U.","year":"2020","unstructured":"Singh T.U.; Parida S.; Lingaraju M.C.; Kesavan M.; Kumar D.; Singh R.K.; Drug repurposing approach to fight COVID-19. Pharmacol Rep 2020,72(6),1479-1508","journal-title":"Pharmacol Rep"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/jmv.26254","volume":"93","author":"Singh S.P.","year":"2021","unstructured":"Singh S.P.; Pritam M.; Pandey B.; Yadav T.P.; Microstructure, pathophysiology, and potential therapeutics of COVID\u201019: A comprehensive review. J Med Virol 2021,93(1),275-299","journal-title":"J Med Virol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nrd2466","volume":"7","author":"Lundberg J.O.","year":"2008","unstructured":"Lundberg J.O.; Weitzberg E.; Gladwin M.T.; The nitrate\u2013nitrite\u2013nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 2008,7(2),156-167","journal-title":"Nat Rev Drug Discov"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3389\/fimmu.2020.02037","volume":"11","author":"Mortaz E.","year":"2020","unstructured":"Mortaz E.; Tabarsi P.; Varahram M.; Folkerts G.; Adcock I.M.; The immune response and immunopathology of COVID-19. Front Immunol 2020,11,2037","journal-title":"Front Immunol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11882-020-00983-9","volume":"21","author":"Udupa A.","year":"2021","unstructured":"Udupa A.; Leverenz D.; Balevic S.J.; Sadun R.E.; Tarrant T.K.; Rogers J.L.; Hydroxychloroquine and COVID-19: A rheumatologist\u2019s take on the lessons learned. Curr Allergy Asthma Rep 2021,21(1),5","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"173372","DOI":"10.1016\/j.ejphar.2020.173372","volume":"883","author":"Chibber P.","year":"2020","unstructured":"Chibber P.; Haq S.A.; Ahmed I.; Andrabi N.I.; Singh G.; Advances in the possible treatment of COVID-19: A review. Eur J Pharmacol 2020,883,173372","journal-title":"Eur J Pharmacol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/art.41301","volume":"72","author":"Mikuls T.R.","year":"2020","unstructured":"Mikuls T.R.; Johnson S.R.; Fraenkel L.; American college of rheumatology guidance for the management of rheumatic disease in adult patients during the covid\u201019 pandemic: version 1. Arthritis Rheumatol 2020,72(8),1241-1251","journal-title":"Arthritis Rheumatol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","volume":"82","author":"Lamb Y.N.","year":"2022","unstructured":"Lamb Y.N.; Nirmatrelvir plus ritonavir: First approval. Drugs 2022,82(5),585-591","journal-title":"Drugs"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"102329","DOI":"10.1016\/j.dsx.2021.102329","volume":"15","author":"Singh A.K.","year":"2021","unstructured":"Singh A.K.; Singh A.; Singh R.; Misra A.; Molnupiravir in COVID-19: A systematic review of literature. Diabetes Metab Syndr 2021,15(6),102329","journal-title":"Diabetes Metab Syndr"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40265-022-01690-7","volume":"82","author":"Heo Y.A.","year":"2022","unstructured":"Heo Y.A.; Sotrovimab: First approval. Drugs 2022,82(4),477-484","journal-title":"Drugs"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"2022.03","DOI":"10.1101\/2022.03.10.22272100","author":"Dougan M.","year":"2022","unstructured":"Dougan M.; Azizad M.; Chen P.; Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19 MedRxiv 2022,2022.03","journal-title":"MedRxiv"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"Levin M.J.","year":"2022","unstructured":"Levin M.J.; Ustianowski A.; De Wit S.; Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of covid-19. N Engl J Med 2022,386(23),2188-2200","journal-title":"N Engl J Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jama.2021.24931","volume":"327","year":"2022","unstructured":"Tixagevimab and Cilgavimab (Evusheld) for pre-exposure prophylaxis of COVID-19. JAMA 2022,327(4),384-385","journal-title":"JAMA"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.freeradbiomed.2020.12.008","volume":"163","author":"Fang W.","year":"2021","unstructured":"Fang W.; Jiang J.; Su L.; The role of NO in COVID-19 and potential therapeutic strategies. Free Radic Biol Med 2021,163,153-162","journal-title":"Free Radic Biol Med"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"101982","DOI":"10.1016\/j.redox.2021.101982","volume":"43","author":"Dominic P.","year":"2021","unstructured":"Dominic P.; Ahmad J.; Bhandari R.; Decreased availability of nitric oxide and hydrogen sulfide is a hallmark of COVID-19. Redox Biol 2021,43,101982","journal-title":"Redox Biol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/sj.ijir.3901256","volume":"16","author":"Ghalayini I.F.","year":"2004","unstructured":"Ghalayini I.F.; Nitric oxide\u2013cyclic GMP pathway with some emphasis on cavernosal contractility. Int J Impot Res 2004,16(6),459-469","journal-title":"Int J Impot Res"},{"key":"ref=68","first-page":"19","year":"2022","unstructured":"Clinical management of COVID-19: Living guideline, 23 June 2022 2022,19-21","journal-title":"Clinical management of COVID-19: Living guideline, 23 June 2022"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/med.21776","volume":"41","author":"Wu Y.","year":"2021","unstructured":"Wu Y.; Li Z.; Zhao Y.S.; Huang Y.Y.; Jiang M.Y.; Luo H.B.; Therapeutic targets and potential agents for the treatment of COVID\u201019. Med Res Rev 2021,41(3),1775-1797","journal-title":"Med Res Rev"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1073\/pnas.1804932115","volume":"115","author":"Radi R.","year":"2018","unstructured":"Radi R.; Oxygen radicals, nitric oxide, and peroxynitrite: Redox pathways in molecular medicine. Proc Natl Acad Sci 2018,115(23),5839-5848","journal-title":"Proc Natl Acad Sci"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1021\/ar800089j","volume":"42","author":"Gladwin M.T.","year":"2009","unstructured":"Gladwin M.T.; Grubina R.; Doyle M.P.; The new chemical biology of nitrite reactions with hemoglobin: R-state catalysis, oxidative denitrosylation, and nitrite reductase\/anhydrase. Acc Chem Res 2009,42(1),157-167","journal-title":"Acc Chem Res"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4103\/ijp.ijp_382_21","volume":"53","author":"Prakash A.","year":"2021","unstructured":"Prakash A.; Kaur S.; Kaur C.; Efficacy and safety of inhaled nitric oxide in the treatment of severe\/critical COVID-19 patients: A systematic review. Indian J Pharmacol 2021,53(3),236-243","journal-title":"Indian J Pharmacol"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"100084","DOI":"10.1016\/j.lanepe.2021.100084","volume":"4","author":"Backer V","year":"2021","unstructured":"Backer V; Sj&#xF6;bring U; Sonne J; A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19. Lancet Reg Heal - Eur 2021,4,100084","journal-title":"Lancet Reg Heal - Eur"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1136\/thx.54.10.947","volume":"54","author":"Lundberg J.O.N.","year":"1999","unstructured":"Lundberg J.O.N.; Weitzberg E.; Nasal nitric oxide in man. Thorax 1999,54(10),947-952","journal-title":"Thorax"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.micinf.2020.05.002","volume":"22","author":"Martel J.","year":"2020","unstructured":"Martel J.; Ko Y.F.; Young J.D.; Ojcius D.M.; Could nasal nitric oxide help to mitigate the severity of COVID-19? Microbes Infect 2020,22(4-5),168-171","journal-title":"Microbes Infect"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1172\/JCI116479","volume":"91","author":"Croen K.D.","year":"1993","unstructured":"Croen K.D.; Evidence for antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication. J Clin Invest 1993,91(6),2446-2452","journal-title":"J Clin Invest"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/0735-1097(94)90859-1","volume":"24","author":"Semigran M.J.","year":"1994","unstructured":"Semigran M.J.; Cockrill B.A.; Kacmarek R.; Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol 1994,24(4),982-988","journal-title":"J Am Coll Cardiol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.4187\/respcare.08265","volume":"65","author":"Walsh B.K.","year":"2020","unstructured":"Walsh B.K.; Inhaled pulmonary vasodilators in the neonatal and pediatric ICU. Respir Care 2020,65(10),1611-1623","journal-title":"Respir Care"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.freeradbiomed.2019.11.029","volume":"152","author":"Barnes M.","year":"2020","unstructured":"Barnes M.; Brisbois E.J.; Clinical use of inhaled nitric oxide: Local and systemic applications. Free Radic Biol Med 2020,152,422-431","journal-title":"Free Radic Biol Med"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1128\/AAC.49.3.1209-1212.2005","volume":"49","author":"Long R.","year":"2005","unstructured":"Long R.; Jones R.; Talbot J.; Inhaled nitric oxide treatment of patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2005,49(3),1209-1212","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.ijsu.2016.05.050","volume":"33","author":"Cannistr&#xE0; M.","year":"2016","unstructured":"Cannistr&#xE0; M.; Ruggiero M.; Zullo A.; Hepatic ischemia reperfusion injury: A systematic review of literature and the role of current drugs and biomarkers. Int J Surg 2016,33(Suppl. 1),S57-S70","journal-title":"Int J Surg"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJM199310283291807","volume":"329","author":"Harris C.C.","year":"1993","unstructured":"Harris C.C.; Hollstein M.; The New England Journal of Medicine Downloaded from nejm.org at Universitaetsbibliothek Wuerzburg on July 18, 2013. For personal use only. No other uses without permission. Copyright&#xA9; 1993 Massachusetts Medical Society. All rights reserved. N Engl J Med 1993,329,1318-1327","journal-title":"N Engl J Med"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/cvr\/cvq139","volume":"87","author":"Dur&#xE1;n W.N.","year":"2010","unstructured":"Dur&#xE1;n W.N.; Breslin J.W.; S&#xE1;nchez F.A.; The NO cascade, eNOS location, and microvascular permeability. Cardiovasc Res 2010,87(2),254-261","journal-title":"Cardiovasc Res"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"jcs.115972","DOI":"10.1242\/jcs.115972","volume":"126","author":"Di Lorenzo A","year":"2013","unstructured":"Di Lorenzo A; Lin MI; Murata T; eNOS derived nitric oxide regulates endothelial barrier function via VE cadherin and Rho GTPases. J Cell Sci 2013,126(Pt 24),jcs.115972","journal-title":"J Cell Sci"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fphys.2012.00218","volume":"3","author":"Cau S.B.A.","year":"2012","unstructured":"Cau S.B.A.; Carneiro F.S.; Tostes R.C.; Differential modulation of nitric oxide synthases in aging: therapeutic opportunities. Front Physiol 2012,3,218","journal-title":"Front Physiol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","volume":"229","author":"Croft M.","year":"2009","unstructured":"Croft M.; So T.; Duan W.; Soroosh P.; The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 2009,229(1),173-191","journal-title":"Immunol Rev"},{"key":"ref=87","author":"Dong M","year":"2020","unstructured":"Dong M; Zhang J; Ma X; Tan J; Chen L.; Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19. The COVID-19 resource centre is hosted on Elsevier Connect , the company\u2019s public news and information Available at: 2020","journal-title":"The COVID-19 resource centre is hosted on Elsevier Connect , the company\u2019s public news and information"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jcf.2012.01.003","volume":"11","author":"Miller C.","year":"2012","unstructured":"Miller C.; Miller M.; McMullin B.; A phase I clinical study of inhaled nitric oxide in healthy adults. J Cyst Fibros 2012,11(4),324-331","journal-title":"J Cyst Fibros"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","volume":"126","author":"Gheblawi M.","year":"2020","unstructured":"Gheblawi M.; Wang K.; Viveiros A.; Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system. Circ Res 2020,126(10),1456-1474","journal-title":"Circ Res"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1124\/pr.120.019240","volume":"72","author":"Kapil V.","year":"2020","unstructured":"Kapil V.; Khambata R.S.; Jones D.A.; The noncanonical pathway for in vivo nitric oxide generation: The nitrate-nitrite-nitric oxide pathway. Pharmacol Rev 2020,72(3),692-766","journal-title":"Pharmacol Rev"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3390\/biomedicines10020369","volume":"10","author":"Kamenshchikov N.O.","year":"2022","unstructured":"Kamenshchikov N.O.; Berra L.; Carroll R.W.; Therapeutic effects of inhaled nitric oxide therapy in COVID-19 patients. Biomedicines 2022,10(2),369","journal-title":"Biomedicines"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2217\/imt-2021-0168","volume":"14","author":"Chavda V.P.","year":"2022","unstructured":"Chavda V.P.; Kapadia C.; Soni S.; A global picture: therapeutic perspectives for COVID-19. Immunotherapy 2022,14(5),351-371","journal-title":"Immunotherapy"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"105252","DOI":"10.1016\/j.antiviral.2022.105252","volume":"198","author":"Vangeel L.","year":"2022","unstructured":"Vangeel L.; Chiu W.; De Jonghe S.; Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res 2022,198,105252","journal-title":"Antiviral Res"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/14712598.2022.2078160","volume":"22","author":"Chavda V.P.","year":"2022","unstructured":"Chavda V.P.; Prajapati R.; Lathigara D.; Therapeutic monoclonal antibodies for COVID-19 management: An update. Expert Opin Biol Ther 2022,22(6),763-780","journal-title":"Expert Opin Biol Ther"},{"key":"ref=95","first-page":"1","author":"More R","year":"2021","unstructured":"More R; Kingsland J; Sanfins A; Images G.;  COVID-19 : Nitric oxide shows promise as antiviral treatment 2021,1-14","journal-title":"COVID-19 : Nitric oxide shows promise as antiviral treatment"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"101734","DOI":"10.1016\/j.redox.2020.101734","volume":"37","author":"Akaberi D.","year":"2020","unstructured":"Akaberi D.; Krambrich J.; Ling J.; Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro. Redox Biol 2020,37,101734","journal-title":"Redox Biol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"fso.15.59","DOI":"10.4155\/fso.15.59","volume":"1","author":"Lancaster JR","year":"2015","unstructured":"Lancaster JR; Nitric oxide: a brief overview of chemical and physical properties relevant to therapeutic applications. Future Sci OA 2015,1(1),fso.15.59","journal-title":"Future Sci OA"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2009.09.007","volume":"395","author":"&#xC5;kerstr&#xF6;m S.","year":"2009","unstructured":"&#xC5;kerstr&#xF6;m S.; Gunalan V.; Keng C.T.; Tan Y.J.; Mirazimi A.; Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affected. Virology 2009,395(1),1-9","journal-title":"Virology"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.niox.2013.03.007","volume":"31","author":"Regev-Shoshani G.","year":"2013","unstructured":"Regev-Shoshani G.; Vimalanathan S.; McMullin B.; Road J.; Av-Gay Y.; Miller C.; Gaseous nitric oxide reduces influenza infectivity in vitro. Nitric Oxide 2013,31,48-53","journal-title":"Nitric Oxide"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/157016112798829760","volume":"10","author":"Tousoulis D.","year":"2012","unstructured":"Tousoulis D.; Kampoli A.M.; Tentolouris Nikolaos Papageorgiou C.; Stefanadis C.; Stefanadis C.; The role of nitric oxide on endothelial function. Curr Vasc Pharmacol 2012,10(1),4-18","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1378\/chest.12-1215","volume":"143","author":"Budinger G.R.S.","year":"2013","unstructured":"Budinger G.R.S.; Mutlu G.M.; Balancing the risks and benefits of oxygen therapy in critically III adults. Chest 2013,143(4),1151-1162","journal-title":"Chest"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"046003","DOI":"10.1088\/1752-7163\/ac7d6a","volume":"16","author":"Tamminen P.J.","year":"2022","unstructured":"Tamminen P.J.; Kerimov D.M.; Viskari H.; Aittoniemi J.; Syrj&#xE4;nen J.; Lehtim&#xE4;ki L.; Nasal nitric oxide is decreased in acute mild COVID-19 and related to viral load. J Breath Res 2022,16(4),046003","journal-title":"J Breath Res"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3390\/jcm9051417","volume":"9","author":"Sardu C.","year":"2020","unstructured":"Sardu C.; Gambardella J.; Morelli M.B.; Wang X.; Marfella R.; Santulli G.; Hypertension, thrombosis, kidney failure, and diabetes: Is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J Clin Med 2020,9(5),1417","journal-title":"J Clin Med"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13613-020-00681-9","volume":"10","author":"Kobayashi J.","year":"2020","unstructured":"Kobayashi J.; Murata I.; Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome. Ann Intensive Care 2020,10(1),61","journal-title":"Ann Intensive Care"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/ehf2.13023","volume":"8","author":"Feng W-X.","year":"2021","unstructured":"Feng W-X.; Yang Y.; Wen J.; Liu Y-X.; Liu L.; Feng C.; Implication of inhaled nitric oxide for the treatment of critically ill COVID-19 patients with pulmonary hypertension. ESC Heart Fail 2021,8,714-718","journal-title":"ESC Heart Fail"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"100036","DOI":"10.1016\/j.lansea.2022.100036","volume":"3","author":"Tandon M","year":"2022","unstructured":"Tandon M; Wu W; Moore K; SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial. Lancet Regional Health - Southeast Asia 2022,3,100036","journal-title":"Lancet Regional Health - Southeast Asia"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"103925","DOI":"10.1016\/j.ebiom.2022.103925","volume":"77","author":"Ferrari M.","year":"2022","unstructured":"Ferrari M.; Protti A.; Nitric oxide in COVID-19: Too little of a good thing? EBioMedicine 2022,77,103925","journal-title":"EBioMedicine"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/IM9.0000000000000079","volume":"4","author":"Moni M.","year":"2022","unstructured":"Moni M.; Madathil T.; Sathyapalan D.T.; Clinical efficacy of inhaled nitric oxide in preventing the progression of moderate to severe COVID-19 and its correlation to viral clearance: Results of a pilot study. Infect Microbes Dis 2022,4,26-33 https:\/\/journals.lww.com\/imd\/Fulltext\/2022\/03000\/Clinical_Efficacy_of_Inhaled_Nitric_Oxide_in.5.aspx","journal-title":"Infect Microbes Dis"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/AOG.0000000000004847","volume":"140","author":"Valsecchi C.","year":"2022","unstructured":"Valsecchi C.; Winterton D.; Safaee Fakhr B.; Collaborators, high-dose inhaled nitric oxide for the treatment of spontaneously breathing pregnant patients with severe coronavirus disease 2019 (COVID-19) pneumonia. Obstet Gynecol 2022,140(2),195-203 https:\/\/journals.lww.com\/greenjournal\/Fulltext\/9900\/High_Dose_Inhaled_Nitric_Oxide_for_the_Treatment.526.aspx","journal-title":"Obstet Gynecol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"e0270646","DOI":"10.1371\/journal.pone.0270646","volume":"17","author":"Poonam P.B.H.","year":"2022","unstructured":"Poonam P.B.H.; Koscik R.; Nguyen T.; Rikhi S.; Lin H.M.; Nitric oxide versus epoprostenol for refractory hypoxemia in Covid-19. PLoS One 2022,17(6),e0270646","journal-title":"PLoS One"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/1753466620933510","author":"Parikh R.","year":"2020","unstructured":"Parikh R.; Wilson C.; Weinberg J.; Gavin D.; Murphy J.; Reardon C.C.; Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients. Ther Adv Respir Dis 2020,14","journal-title":"Ther Adv Respir Dis"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.niox.2021.08.003","volume":"116","author":"Safaee Fakhr B.","year":"2021","unstructured":"Safaee Fakhr B.; Di Fenza R.; Gianni S.; Inhaled high dose nitric oxide is a safe and effective respiratory treatment in spontaneous breathing hospitalized patients with COVID-19 pneumonia. Nitric Oxide 2021,116,7-13","journal-title":"Nitric Oxide"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/mp.2015.166","volume":"21","author":"Quintana D.S.","year":"2016","unstructured":"Quintana D.S.; Guastella A.J.; Westlye L.T.; Andreassen O.A.; The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders. Mol Psychiatry 2016,21(1),29-38","journal-title":"Mol Psychiatry"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","volume":"143","author":"Erd\u0151 F","year":"2018","unstructured":"Erd\u0151 F; Bors LA; Farkas D; Bajza &#xC1;; Gizurarson S; Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull 2018,143,155-170","journal-title":"Brain Res Bull"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1128\/JVI.79.3.1966-1969.2005","volume":"79","author":"&#xC5;kerstr&#xF6;m S.","year":"2005","unstructured":"&#xC5;kerstr&#xF6;m S.; Mousavi-Jazi M.; Klingstr&#xF6;m J.; Leijon M.; Lundkvist &#xC5;.; Mirazimi A.; Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol 2005,79(3),1966-1969","journal-title":"J Virol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"2020.03.09.20033530","DOI":"10.1101\/2020.03.09.20033530","author":"Lei C.","year":"2020","unstructured":"Lei C.; Su B.; Dong H.; Protocol of a randomized controlled trial testing inhaled Nitric Oxide in mechanically ventilated patients with severe acute respiratory syndrome in COVID-19 (SARS-CoV-2) MedRxiv 2020,2020.03.09.20033530","journal-title":"MedRxiv"},{"key":"ref=117","first-page":"e13884","author":"Swathi Krishna S.","year":"2021","unstructured":"Swathi Krishna S.; Thennavan A.; Kanthlal S.K.; Dietary foods containing nitric oxide donors can be early curators of SARS-CoV-2 infection: A possible role in the immune system. J Food Biochem 2021,e13884","journal-title":"J Food Biochem"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1016\/j.bja.2020.10.011","volume":"126","author":"Longobardo A.","year":"2021","unstructured":"Longobardo A.; Montanari C.; Shulman R.; Benhalim S.; Singer M.; Arulkumaran N.; Inhaled nitric oxide minimally improves oxygenation in COVID-19 related acute respiratory distress syndrome. Br J Anaesth 2021,126(1),e44-e46","journal-title":"Br J Anaesth"},{"key":"ref=119","year":"2021","unstructured":"Sanotize Research and Development corp. Nitric Oxide Releasing Solutions to Prevent and Treat Mild\/Moderate COVID-19 Infection (NOCOVID). ClinicalTrialsGov Available from:  (Accessed on: April 25, 2021).2021","journal-title":"ClinicalTrialsGov"},{"key":"ref=120","author":"Parkins K.","year":"2021","unstructured":"Parkins K.; SaNOtize\u2019s &#x201C;revolutionary&#x201D; COVID-19 nasal spray bolstered by Phase II trial data. Clin Trials Arena Available from:  (accessed April 25, 2021).2021","journal-title":"Clin Trials Arena"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4037\/ccn2018836","volume":"38","author":"Tucker C.","year":"2018","unstructured":"Tucker C.; Tucker L.; Brown K.; The intranasal route as an alternative method of medication administration. Crit Care Nurse 2018,38(5),26-31","journal-title":"Crit Care Nurse"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/toxsci\/59.1.5","volume":"59","author":"Weinberger B.","year":"2001","unstructured":"Weinberger B.; Laskin D.L.; Heck D.E.; Laskin J.D.; The toxicology of inhaled nitric oxide. Toxicol Sci 2001,59(1),5-16","journal-title":"Toxicol Sci"},{"key":"ref=123","year":"2021","unstructured":"UK Clinical Trial Confirms SaNOtize\u2019s Breakthrough Treatment for COVID-19 BusinessWire SaNOtizeAvailable from: 2021","journal-title":"UK Clinical Trial Confirms SaNOtize\u2019s Breakthrough Treatment for COVID-19 BusinessWire"},{"key":"ref=124","year":"2021","unstructured":"LungFit&#xAE; PH PMA. Revolutionizing Nitric Oxide Therapy. Beyondair Available from:  (Accessed on: April 25, 2021).2021","journal-title":"Beyondair"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jinf.2021.05.009","volume":"83","author":"Winchester S.","year":"2021","unstructured":"Winchester S.; John S.; Jabbar K.; John I.; Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection. J Infect 2021,83(2),237-279","journal-title":"J Infect"},{"key":"ref=126","unstructured":"Vero Biotech Recalls GENOSYL DS ; Nitric Oxide Delivery System Due to Software Error U.S Food","journal-title":"Vero Biotech Recalls GENOSYL DS ; Nitric Oxide Delivery System Due to Software Error"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1080\/14787210.2021.1908127","volume":"19","author":"Shmuel K.","year":"2021","unstructured":"Shmuel K.; Dalia M.; Tair L.; Yaakov N.; Low pH Hypromellose (Taffix) nasal powder spray could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: an observational prospective open label user survey. Expert Rev Anti Infect Ther 2021,19(10),1325-1330","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=128","first-page":"73","volume":"27","author":"Hull D.","year":"2007","unstructured":"Hull D.; Rennie P.; Noronha A.; Effects of creating a non-specific, virus-hostile environment in the nasopharynx on symptoms and duration of common cold. Acta Otorhinolaryngol Ital 2007,27,73-77","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"ref=129","year":"2020","unstructured":"VERO Biotech, TechnologyAvailable from:  (Accessed on: April 25, 2021).2020"},{"key":"ref=130","first-page":"1","year":"2021","unstructured":"Viraleze ViralezeTM antiviral nasal spray Available from: 2021,1-3","journal-title":"Viraleze ViralezeTM antiviral nasal spray"},{"key":"ref=131","unstructured":"Australia\u2019s Starpharma\u2019s launches COVID-19 antiviral nasal spray VIRALEZE in the UK BioSpectrumAvailable from:","journal-title":"Australia\u2019s Starpharma\u2019s launches COVID-19 antiviral nasal spray VIRALEZE in the UK"},{"key":"ref=132","unstructured":"Viralezetm targets the area in the nasal cavity where respiratory viruses that cause colds, flu and more severe respiratory illness, such as covid-19, first attach and start to multiply WHOAvailable from:","journal-title":"Viralezetm targets the area in the nasal cavity where respiratory viruses that cause colds, flu and more severe respiratory illness, such as covid-19, first attach and start to multiply"},{"key":"ref=133","unstructured":"Mallinckrodt Pharmaceuticals INOmax&#xAE; (nitric oxide) Available from:","journal-title":"Mallinckrodt Pharmaceuticals INOmax&#xAE; (nitric oxide)"},{"key":"ref=134","first-page":"30","author":"Syndrome D.","year":"2020","unstructured":"Syndrome D.; Mallinckrodt supports investigator-initiated study at massachusetts general hospital to assess effectiveness of inhaled nitric oxide in patients with severe acute respiratory. Distress Syndrome Due to COVID-19. Mallinckrodt Pharmaceuticals Available from: 2020,30","journal-title":"Mallinckrodt Pharmaceuticals"},{"key":"ref=135","author":"Ards C.","unstructured":"Ards C.;  BRIEF-Mallinckrodt evaluates potential role for inhaled nitric oxide to treat covid-19 associated lung complications Available from:","journal-title":"BRIEF-Mallinckrodt evaluates potential role for inhaled nitric oxide to treat covid-19 associated lung complications"},{"key":"ref=136","first-page":"1","author":"Lung C.A.","year":"2021","unstructured":"Lung C.A.; Mallinckrodt Evaluates the Potential Role for Inhaled Nitric Oxide Scientific. Governmental and Regulatory Agencies 2021,1-4","journal-title":"Governmental and Regulatory Agencies"},{"key":"ref=137","first-page":"1","author":"Corp D.","year":"2021","unstructured":"Corp D.; Nitric Oxide Nasal Spray (NONS). Clinical Trial 2021,1-5","journal-title":"Clinical Trial"},{"key":"ref=138","unstructured":"Nitric oxide gas inhalation in severe acute respiratory syndrome in COVID-19 (NOSARSCOVID) Massachusetts General HospitalAvailable from:","journal-title":"Nitric oxide gas inhalation in severe acute respiratory syndrome in COVID-19 (NOSARSCOVID)"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S1357-2725(96)00167-7","volume":"29","author":"Robbins R.A.","year":"1997","unstructured":"Robbins R.A.; Grisham M.B.; Nitric oxide. Int J Biochem Cell Biol 1997,29(6),857-860","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.niox.2015.06.002","volume":"49","author":"Benedetto M.","year":"2015","unstructured":"Benedetto M.; Romano R.; Baca G.; Inhaled nitric oxide in cardiac surgery: Evidence or tradition? Nitric Oxide 2015,49,67-79","journal-title":"Nitric Oxide"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"CD002787","DOI":"10.1002\/14651858.CD002787.pub3","volume":"2018","author":"Gebistorf F.","year":"2016","unstructured":"Gebistorf F.; Karam O.; Wetterslev J.; Afshari A.; Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Libr 2016,2018(12),CD002787","journal-title":"Cochrane Libr"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s13337-021-00702-6","volume":"32","author":"Srivastava S.","year":"2021","unstructured":"Srivastava S.; Garg I.; Hembrom A.A.; Kumar B.; Assessment of nitric oxide (NO) potential to mitigate COVID-19 severity. Virusdisease 2021,32(3),589-594","journal-title":"Virusdisease"},{"key":"ref=143","year":"2022","unstructured":"Medical management guidelines for nitrogen oxides. ATSDR Agency Toxic Subst Dis Regist CDCAvailable from:  (accessed September 3, 2022).2022","journal-title":"ATSDR Agency Toxic Subst Dis Regist"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"fso.15.35","DOI":"10.4155\/fso.15.35","volume":"1","author":"Wong VWC","year":"2015","unstructured":"Wong VWC; Lerner E; Nitric oxide inhibition strategies. Future Sci OA 2015,1(1),fso.15.35","journal-title":"Future Sci OA"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612829666221024124848","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/210331\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612829666221024124848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T04:19:59Z","timestamp":1691727599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/210331\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":144,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612829666221024124848","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}